September 16, 2020 -- AVM Biotechnology received authorization for an investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to evaluate its proprietary drug, AVM0703, in the treatment of acute respiratory distress syndrome (ARDS) mediated by COVID-19 or influenza patients.
AVM0703 is a proprietary formulation of high-concentration dexamethasone, which mobilizes natural killer T cells, cytotoxic T cells, and dendritic cells. The cells are highly potent against difficult-to-treat cancers and can be used to eliminate abnormal virus-infected cells, as in COVID-19 or influenza-mediated ARDS. A single dose of AVM0703 formulation of dexamethasone triggers critical immune system activation, according to the firm.
The new study will study two populations, one with COVID-19-mediated moderate to severe ARDS and the other with influenza-mediated severe ARDS.
The drug was previously authorized for a study evaluating its effectiveness for treatment of refractory/relapsed non-Hodgkin's lymphoma.